https://www.sciencedirect.com/science/article/pii/S1043661826001428
chatGPT:
Summary
This is a broad 2026 review article on mitochondria-targeted therapeutic strategies for neurodegenerative diseases, mainly Alzheimer’s disease and Parkinson’s disease. The paper argues that mitochondrial dysfunction is not just a downstream consequence of neurodegeneration, but an early and potentially disease-driving process involving reduced ATP production, oxidative stress, impaired mitochondrial dynamics, defective mitophagy, disrupted calcium handling, mtDNA damage, and impaired biogenesis.
The review first explains normal mitochondrial function: oxidative phosphorylation, membrane potential, calcium buffering, protein import, fission/fusion, PGC-1α/NRF/TFAM-driven biogenesis, PINK1/Parkin mitophagy, receptor-mediated mitophagy, mitochondrial-derived vesicles, and axonal transport. The figures on pages 2–3 are useful because they visually contrast healthy mitochondrial transport and quality-control pathways with dysfunctional neurons showing ROS accumulation, impaired mitophagy, protein aggregates, calcium stress and defective dynamics.
It then links these processes to AD and PD. In AD, amyloid-β and phosphorylated tau are presented as interacting with mitochondrial import, respiratory complexes, calcium balance, mPTP opening, fission/fusion and transport. In PD, α-synuclein, PINK1/Parkin impairment, complex I dysfunction and defective mitophagy are emphasized. The review also includes an interesting sex/estrogen dimension, arguing that loss of estrogenic mitochondrial support after menopause may contribute to AD vulnerability, while male susceptibility in PD may relate partly to weaker mitochondrial protection.
Therapeutically, the paper surveys lifestyle interventions, especially exercise, ketogenic and Mediterranean/MIND-style diets, and bioactive food compounds such as blueberries, green tea catechins, polyphenols and omega-3s. It also covers small molecules and more advanced approaches: CoQ10/MitoQ-type antioxidants, mitophagy enhancers, urolithin A, rapamycin, USP30 inhibitors, PINK1/Parkin activators, nanoparticles, mitochondrial delivery platforms, PROTAC-style approaches, mtDNA editing and mitochondrial transfer. The authors’ central conclusion is cautious: many interventions look promising in preclinical models, but effects are often preventive rather than restorative, and clinical evidence remains limited.
What is novel or useful
The paper’s novelty is not a single new experimental finding, because it is a review, but rather its integrative framing. It brings together classical mitochondrial mechanisms, AD/PD pathology, lifestyle interventions, phytochemicals, small molecules and next-generation mitochondrial technologies into one therapeutic map.
The most useful aspects are:
-
It treats mitochondrial dysfunction as a network problem, not merely as “oxidative stress”. It covers bioenergetics, mitophagy, mitochondrial dynamics, calcium handling, protein import, mtDNA and transport together.
-
It distinguishes prevention from restoration. This is important. Many compounds protect cells before a toxin or stressor is applied, but that does not mean they can reverse established neurodegeneration.
-
It includes translation barriers explicitly. The authors note that nanoparticles, MITO-Porters, PROTACs, mitochondrial transplantation and mtDNA editing have not yet reached clinical trials in neurodegenerative disease, largely because of delivery, dosing, safety, heteroplasmy and model-validity problems.
-
It highlights sex-specific mitochondrial biology. The menopause/estrogen discussion is a useful addition, although still speculative in clinical terms.
-
It correctly emphasizes patient stratification and biomarkers. The paper argues that success will likely depend on early intervention, mitochondrial-health biomarkers, and stratification by age, sex, genetics and metabolic state.
Critique
The main weakness is that the review is very broad, perhaps too broad. It covers exercise, diet, phytochemicals, antioxidants, mitophagy drugs, hormone replacement, nanoparticles, mtDNA editing and mitochondrial transfer. That breadth is useful as a landscape review, but it means many sections inevitably become descriptive rather than deeply evaluative.
A second issue is that much of the evidence base remains preclinical and preventive. The authors acknowledge this, but it is still the central limitation of the field. Protection in young animal models, immortalized cell lines, toxin models, APP/PS1 mice or short-term oxidative-stress paradigms does not necessarily translate into meaningful benefit in older humans with established AD or PD.
A third limitation is the lack of hard prioritisation. The paper lists many possible interventions, but does not clearly rank which are most plausible, safest, nearest to translation, or mechanistically strongest. For example, exercise and metabolic interventions have a very different evidence and safety profile from mtDNA editing or mitochondrial transplantation, but the review sometimes places them in the same broad therapeutic continuum.
The phytochemical sections are useful but vulnerable to the usual problem: high concentrations, poor bioavailability, mixed extracts, unclear brain exposure and weak clinical endpoints. For compounds such as EGCG, blueberry anthocyanins or olive-oil polyphenols, antioxidant and mitochondrial effects in vitro may not reflect achievable human CNS concentrations.
The paper could also be more sceptical about whether “improving mitochondrial function” is always beneficial. Increasing biogenesis, mitophagy or membrane potential may help in some contexts but could be harmful in others, especially where cancer risk, senescent-cell survival, inflammatory activation or maladaptive compensation are involved.
Bottom line
This is a good, wide-ranging review of mitochondrial therapeutic strategies in AD and PD. Its best contribution is the integrated map of mitochondrial dysfunction and the careful acknowledgement that most candidate interventions remain preclinical, preventive and delivery-limited. Its weakness is that it surveys almost everything without enough prioritisation or quantitative comparison. The realistic conclusion is that mitochondrial targeting is highly plausible as an early, preventive or adjunctive strategy, but there is still little evidence that current approaches can robustly reverse established neurodegenerative disease.
second prompt for a list of the interventions
Simple list of interventions discussed in the paper:
- Physical exercise
- Ketogenic diet
- Mediterranean diet / MIND diet
- Blueberries / Vaccinium extracts
- Green tea catechins, especially EGCG
- Olive-oil polyphenols, such as hydroxytyrosol and oleuropein
- Omega-3 fatty acids, including DHA and EPA
- Coenzyme Q10
- MitoQ and other mitochondria-targeted antioxidants
- Oxaloacetate
- Urolithin A
- Rapamycin / mTOR modulation
- NAD⁺-boosting approaches
- PGC-1α / mitochondrial biogenesis enhancers
- Mitophagy enhancers
- PINK1/Parkin pathway activators
- USP30 inhibitors
- Drp1 / mitochondrial fission modulators
- Mitochondria-targeted nanoparticles
- MITO-Porter delivery systems
- Mitochondria-targeted PROTAC-like approaches
- mtDNA editing
- Mitochondrial transfer / transplantation
- Biomarker-guided mitochondrial profiling
- Sex-specific or hormone-related mitochondrial strategies, especially estrogen-related approaches
The paper frames these mostly as preventive or supportive mitochondrial interventions, with many still at preclinical or early translational stages.